A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-02-20
Target enrollment:
Participant gender:
Summary
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate
multiple regimens in metastatic pancreatic cancer.
Primary Objectives
- To compare each investigational arm versus standard of care (SOC) for superiority in
overall survival in 1st and/or 2nd line metastatic pancreatic cancer patients and
determine which, if any, patients benefit from each investigational arm.
Secondary Objectives
- To determine short and long-term safety signals of each investigational arm in
pancreatic cancer patients vs. SOC.
- To determine progression-free survival (PFS) for each investigational arm vs. SOC.
- Rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever
occurs first).
- Rate of clinical benefit; duration of clinical benefit.